Logomix Biotechnology, Inc.
PrivateLast Round
Series A
Jul 30, 2025
Total Funding Raised
$21.9M
Momentum Score
50 /100
Company Overview
Logomix Biotechnology, Inc. is a synthetic biology company that is reshaping human genome engineering through its proprietary Geno-Writing™ platform. This technology enables the precise and large-scale engineering of genomic sequences, spanning megabases, within human induced pluripotent stem cells (iPSCs). The company's focus is on developing multi-functionalized cells for the fields of cell therapy and regenerative medicine. Logomix aims to build a foundational technology to bring innovative and scalable cell treatments to patients globally, positioning its platform as a core enabler within the bioeconomy. Originally founded in Japan, the company is undergoing strategic expansion into the U.S. market to accelerate its business.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Logomix Biotechnology, Inc. Comps
Public and private peers based on sector, stage, and business model.
Logomix Biotechnology, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 30, 2025 | ||||
| Seed | Feb 8, 2023 |
Logomix Biotechnology, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GLOBIS Capital Partners | Series A |
| JAFCO Group Co., Ltd. | Series A |
| MIRAISOZO INVESTMENTS Inc. | Series A |
| Angel Bridge | Series A, Seed |
| ITOCHU Technology Ventures | Series A |
| Norinchukin Capital Co., Ltd. | Series A |
| Delight Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Monthly visitors increased 77% MoM.
- Mar 3, 2026
Partnering with Belgian CDMO Bio Base Europe Pilot Plant.
Logomix Biotechnology, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Logomix Biotechnology, Inc.'s valuation, stock price, and market status.
